• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Striverdi Respimat (olodaterol)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Striverdi Respimat (olodaterol)

  • Profile

Profile

Contact Information

Contact: Boehringer Ingelheim International
Website: https://docs.boehringer-ingelheim.com/Prescribing Information/PIs/Striverdi Respimat/striverdi.pdf?DMW_FORMAT=pdf

Currently Enrolling Trials

    Show More

    General Information

    Striverdi Respimat (olodaterol) inhalation spray is a long-acting beta2-adrenergic agonist. 

    Striverdi Respimat is specifically indicated as a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

    Mechanism of Action

    Striverdi Respimat (olodaterol) inhalation spray is a long-acting beta2-adrenergic agonist. The compound exerts its pharmacological effects by binding and activation of beta2-adrenoceptors after topical administration by inhalation. Activation of these receptors in the airways results in a stimulation of intracellular adenyl cyclase, an enzyme that mediates the synthesis of cyclic-3’, 5’ adenosine monophosphate (cAMP). Elevated levels of cAMP induce bronchodilation by relaxation of airway smooth muscle cells.

    Side Effects

    Adverse effects associated with the use of Striverdi Respimat may include, but are not limited to, the following:

    • nasopharyngitis
    • upper respiratory tract infection
    • bronchitis
    • urinary tract infection
    • cough
    • dizziness
    • rash
    • diarrhea
    • back pain
    • arthralgia

    Dosing/Administration

    Striverdi Respimat is supplied as spray for oral inhalation. The recommended dose is two inhalations once-daily at the same time of day. Do not use more than two inhalations every 24 hours.

    Clinical Trial Results

    The FDA approval of Striverdi Respimat for COPD was based on three dose-ranging trials and eight confirmatory trials. 

    Dose-ranging trials:
    The first COPD dose-ranging trial was a randomized, double-blind, placebo-controlled, single-dose, five-way cross-over trial in 36 patients. Results demonstrated dose-related improvements in forced expiratory volume in one second (FEV1) compared to placebo. The difference in trough FEV1 from placebo for the 2, 5, 10 and 20 mcg doses were 0.07L, 0.10L, 0.11L and 0.12L, respectively. The second COPD dose-ranging trial was a four-week, randomized, double-blind, placebo-controlled, parallel group trial in 405 patients. Dose-related improvements in lung function were also seen, with no added benefit of the 20 mcg dose over the 10 mcg dose. The third trial was a randomized, double blind, four-way crossover dose-regimen trial in 47 patients. Treatment arms included 2 mcg twice-daily, 5 mcg once-daily, 5 mcg twice-daily and 10 mcg once-daily. There was no clear difference between twice-daily and once-daily dosing.

    Confirmatory trials:
    The eight confirmatory trials were four pairs of replicate, randomized, double-blind, placebo-controlled trials in 3533 COPD patients (1281 received the 5 mcg dose, 1284 received the 10 mcg dose). These included four 48-week trials and four six-week crossover trials. In all four 48-week trials, Striverdi Respimat 5 mcg demonstrated significant improvements in FEV1 AUC 0-3hr compared to placebo at week 12 and at week 24. In the four 48-week trials, Striverdi Respimat 5 mcg demonstrated significant improvements in trough FEV1 compared to placebo at week 12 and at week 24. Striverdi Respimat 5 mcg demonstrated a bronchodilatory treatment effect at five minutes after the first dose with a mean increase in FEV1 compared to placebo of 0.11L (range: 0.10L to 0.12L). The 10 mcg dose demonstrated no additional benefit over the 5 mcg dose. Patients treated with Striverdi Respimat 5 mcg used less rescue albuterol compared to patients treated with placebo. 

     

    Approval Date: 2014-07-01
    Company Name: Boehringer Ingelheim
    Back to Listings

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing